English

CYTISINE Cas-no-485-35-8

CAS NO.:485-35-8
Synonyms: LABURNIN;LABURNINE;(1R-5S)-1,2,3,4,5,6-HEXAHYDRO-1,5-METHANO-8H-PYRIDO[1,2-A][1,5]DIAZOCIN-8-ONE;7,11-DIAZATRICYCLO[7.3.1.0(2,7)]TRIDECA-2,4-DIEN-6-ONE;
(-)-Cytisine, (1S,9S)-3,11-Diazatricyclo[7.3.1.03,8]trideca-5,7-dien-4-one, (1R,5S)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-one;
MF: C11H14N2O            MW: 190.24
Purity: ≥99%
Product Manager Email: Joy@coreychem.com
Melting point  154-156 °C (lit.)
Boiling point  218 °C/2 mmHg (lit.)
alpha  D17 -120°
density  1.0815 (rough estimate)
refractive index  1.5700 (estimate)
storage temp.  Keep in dark place,Sealed in dry,2-8°C
solubility  439g/l
pka 6.11, 13.08(at 25℃)
Appearance light yellow powder
Optical Rotation [α]/D -108±3°, c = 1% in ethanol
Water Solubility  439g/L(16 ºC)
Product manager Joy Wu; Joy@coreychem.com
Frequently Asked Questions:
Question 1: What are the key physicochemical characteristics of Cytisine as an API?
 Cytisine is a naturally occurring quinolizidine alkaloid with the molecular formula C₁₁H₁₄N₂O and a molecular weight of 190.24 g/mol.
It is a crystalline solid, typically white to slightly yellow in color, with a melting point of approximately 152–156 °C. It is soluble in ethanol, benzene, acetone or ethyl acetate, and only sparingly soluble in water. 
Its maximum UV absorption occurs at λmax 234 and 309 nm, and it shows an optical rotation of αD −120°, confirming its optically active (−) form.
Question 2: Which pharmacopoeia standards apply to Cytisine, and What does an EP-compliant Certificate of Analysis (COA) for Cytisine typically verify?
Cytisine API can be supplied according to USP, BP, EP, or in-house standards. Commercially available grades typically range from ≥98% to ≥99.0% purity (HPLC). 
A COA for Cytisine compliant with the European Pharmacopoeia (EP9.0) standard typically reports several categories of specification.These generally include: 
content/assay (HPLC) at ≥98.0%, appearance (white to off-white crystalline powder), identification via IR, UV, HPLC retention time, and colour reaction, 
specific rotation (approximately −118° to −125°), melting point (154–156 °C), loss on drying (≤1.0%), sulfated ash / residue on ignition (≤0.2%), heavy metals (≤20 ppm), 
residual solvents (≤0.5%), and microbiological data such as total plate count, yeast & mould (≤100 cfu/g), and the absence of E. coli and Salmonella.
Question 3: What are the main pharmacological advantages of Cytisine over other smoking cessation drugs?
Cytisine is a partial agonist at α4β2 nicotinic acetylcholine receptors (nAChRs), structurally similar to nicotine and varenicline. Its key advantages include:
--Lower toxicity than nicotine while retaining similar receptor engagement;
--Superior efficacy: achieving 54.1% 6-month abstinence versus 31.2% for nicotine replacement therapy (NRT), and showing non-inferiority to varenicline;
--Better tolerability: a 42% lower relative incidence of nausea compared to varenicline;
--High receptor selectivity — 2,945-fold binding selectivity for α4β2 over α7 receptors;
--Approved in the EU and listed by WHO in 2023 as a first-line smoking cessation aid
Question 4: What are the primary applications and market relevance of Cytisine?
Cytisine is used primarily as an oral small-molecule API for smoking cessation, helping manage nicotine dependence. 
It is also being investigated for other applications, including analgesic, antihypertensive, and inotropic activities. 
Beyond Eastern Europe where it has long been used, it is now gaining global recognition following WHO's 2023 recommendation as a first-line cessation aid, making it a product of growing commercial and clinical relevance.
Application 1:  Smoking Cessation Therapy (Primary Use)
Cytisine's primary and most established use is as a smoking cessation aid. As a partial agonist at the α4β2 nicotinic acetylcholine receptors, it mimics nicotine's effects to reduce cravings 
and withdrawal symptoms without the reinforcing reward of tobacco. It has been used for decades in Eastern Europe under brand names such as Tabex® and Desmoxan. 
Its clinical value is underscored by the fact that the WHO's 2024 Tobacco Cessation Guidelines include cytisine as a first-line medication for treating tobacco use. 
It was also added to the WHO Essential Medicines List in 2025 (as cytisinicline, tablet 1.5 mg, ATC N07BA04) for nicotine dependence.

Application 2:Cost-Effective Value in Public Health
Cytisine offers significant economic and public health value as a low-cost alternative. WHO notes that cytisine can serve as a viable alternative for low- and middle-income countries 
where more expensive pharmacotherapies like varenicline may be less accessible. Its plant-derived natural origin and shorter treatment course contribute to its cost-effectiveness, 
positioning it as a competitive alternative to more expensive synthetic smoking-cessation drugs.
Application 3: Cardiovascular Health Benefits
Quitting smoking with cytisine provides secondary cardiovascular benefits, including reduced heart rate, blood pressure, and lowered risk of heart attack and stroke. 
These cardiovascular improvements are valuable outcomes associated with successful nicotine cessation.
Application 4: Emerging Therapeutic and Research Applications
Beyond smoking cessation, cytisine's cholinergic activity has opened up emerging applications in:
--Weight management, cognitive enhancement, and mental health disorders, driven by its cholinergic activity;
--Cancer treatment research, antimicrobial activities, and even regulation of plant growth;
--Its potential as a chemical reagent in pharmaceutical synthesis and neurological research;
--In dietary supplements and nutraceuticals, where it is used in health care capsules, tablets, and solid beverages with claims of nerve regulation, anti-fatigue, metabolic balance regulation, and antioxidant effects.
Conventional packaging:
100g,1KG,5KG,10KG in aluminium foil bag or sealed bottle in fiber box;
Packaging according to customer requirements.
Storage Conditions:
Please store at dry and cool place
For further information about the product, please contact:
Product Manager Email:Joy@coreychem.com
Get a quote
You can also fill out our online message form and we will contact you within 24 hours.